R&D of Innovative Medicines

The group has 9 innovative drugs under development in 2023, of which 5 are focused on respiratory diseases. These drugs include the dual-target new drug DBM-1152A (Shuobai) used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease, as well as several other new drugs that have entered phase I clinical trials. In addition, Health Element has also entered into strategic cooperation with multiple companies, such as the analgesic new drug FZ008-145 in cooperation with Fermion, the TSLP monoclonal antibody QX008N in cooperation with Quanxin Bio, the anti-IL-4Ra long-acting monoclonal antibody BA2101 injection in cooperation with Boan Bio, and the small molecule inhibitor in cooperation with Bayer. These collaborations further enrich the product line of Health Element Pharmaceutical and promote its rapid development in the field of innovative drugs.

 

In terms of innovative drug research and development, we have a mature platform for the development of biological innovative drug monoclonal antibodies and recombinant proteins. Among them, (i) recombinant human chorionic gonadotropin for injection has been approved for production; (ii) the recombinant novel coronavirus fusion protein vaccine (Likang V-01) has been approved for emergency use in China's sequential immunization

March 2024

Through collaboration with Bayer, we have obtained the exclusive license for the domestic development, commercialization, and production of an oral drug for COPD. This drug works by inhibiting prolyl endopeptidase (PREP) activity, preventing the production of COPD inflammatory mediators, and is expected to bring new treatment strategies for COPD patients.

January 26, 2024

A novel inhaled anti-IL-4Rα monoclonal antibody has been introduced. This drug is also used to treat respiratory diseases such as asthma and COPD. Phase I clinical trials of the anti-IL-4Rα monoclonal antibody have been completed, and Phase II clinical trials have begun.

November 2023

Introducing a highly selective second-generation Nav1.8 inhibitor, an innovative drug for pain treatment, expected to be highly effective and non-addictive. Health Yuan is responsible for subsequent clinical research and application for production of this drug.

November 2023

Acquired rights to an anti-TSLP monoclonal antibody, a drug used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The anti-TSLP monoclonal antibody is currently undergoing Phase II clinical trials for asthma in China.

April 2023

An exclusive license agreement for a new antiviral drug against influenza in Greater China has been reached. The new drug was submitted for production in August and is expected to be launched next year.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

%E7%AC%AC%E4%B8%80%EF%BC%8C%E6%9C%80%EF%BC%8C%E4%BC%98%E7%A7%80%EF%BC%8C%E5%A2%9E%E5%BC%BA%EF%BC%8C%E4%B8%80%E6%B5%81%EF%BC%8C%E5%8D%93%E8%B6%8A%EF%BC%8C%E9%A2%86%E5%85%88%EF%BC%8C%E5%85%88%E8%BF%9B%EF%BC%8C%E5%BC%95%E9%A2%86,顶尖,首个,龙头,知名

Sorry，当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry，The current column has no content!

You can view other columns or return Home